Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 8/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795903 | 0.93 | NPC1 (0.65) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3081851 | 0.93 | NPC1 (0.65) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3084891 | 0.90 | MAPT (0.55) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30794949 | 0.90 | MAPT (0.54) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3077593 | 0.90 | MAPT (0.54) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3080735 | 0.88 | DRD2 (0.52) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3086698 | 0.85 | DRD2 (0.56) | NPC1RAB9ATSHRKMT2AGAA | |
| SCHEMBL28972664 | 0.82 | ADAMTS5 (0.61) | MAPTTSHRKMT2ADRD2DRD3 | |
| SCHEMBL3082219 | 0.81 | NPC1 (0.74) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3799761 | 0.81 | KMT2A (0.67) | NPC1MAPTSMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | claimed |
| EP-2164837-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-03-24 | — | — | EP | claimed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| EP-2164837-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GRM5, GRIK5, GRM1 | NPC1 1352/4885MAPT 1435/4885RAB9A 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.